Description: Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines in the field of neuroscience.
neuroscience (694) oncology (610) neurology (405) orphan (237) schizophrenia (204) bipolar i disorder (9) lybalvi alks 1140 lybalvi™ (olanzapine and samidorphan) nemvaleukin alfa
Discover Alkermes
July 26, 2023 Alkermes plc Reports Second Quarter 2023 Financial Results
June 29, 2023 Alkermes Shareholders Re-Elect All Seven Company Director Nominees at 2023 Annual General Meeting of Shareholders